Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of obesity on aspirin acetylation of COX1/COX2 in colorectal cancer
2024-515251-37-00Phase 2Authorised
- Sponsor
- IIS Aragón
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of aspirin in colorectal cancer (CRC) (2 arms), sponsored by IIS Aragón. Primary endpoint: Effect of aspirin on COX-1 and COX-2 acetylation in colorectal cancer patients. Planned start Nov 2024; status: authorised.
02
Drugs
aspirin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-515251-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515251-37-00.